Health Care · Services-Misc Health & Allied Services, NEC

DVA DaVita SEC Filings & Insider Trading Activity 2026

company
CIK 927066104 filings
S&P 500

DVA at a glance

DaVita (DVA, SEC CIK 927066) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), DaVita (DVA) reported revenue of $13.6 billion (up 6.5% from FY2024) and net income of $746.8 million. Diluted EPS was $9.84.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding DaVita (DVA) shares worth $7.8 billion in 13F-HR filings.
  • In the last 90 days, DVA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($69.0M) on Form 4, a net sale of $69.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$13.6B
+6.5% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$69.0M
13F holders
36 funds
$7.8B · −1 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Providing kidney care services with significant revenues from commercial insurance and government programs like Medicare, Medicaid, and Veterans Affairs
  • New emphasis: Expansion in integrated kidney care offerings including home-based dialysis, U.S. integrated kidney care business, and ancillary services
  • Strategic shift: Increased focus on negotiating private payor contracts amid downward reimbursement pressures and evolving value-based care models
  • Quantitative metric: Approximately 200,500 U.S. dialysis patients managed, with commercial payors generating nearly all profit from dialysis treatment
  • Noteworthy risk: Severe 2024 supply chain disruption from a natural disaster caused increased expenses and slowed growth in home dialysis business

Risk Factors

  • Legal risk: accrual for potential third-party judgment costs of $25 million for unspecified legal matters
  • Macroeconomic exposure: $10.16 billion long-term debt principal maturity with $5.29 billion due after 2030
  • Operational risk: revenue estimating risk up to 1% of revenue, impacting ~5% of U.S. dialysis operating income due to complex payor billing
  • Competitive risk: goodwill impairment triggered by changes in reimbursement structure or market conditions affecting segments
  • Financial risk: $1.53 billion potential cash obligations from put provisions for noncontrolling interests in dialysis partnerships

Management Discussion & Analysis

  • Forward-looking risks include reimbursement rate declines, patient mix shifts, and increased competition pressures
  • Cybersecurity incident in 2025 noted, impacting billing systems and cash flow variability risks
  • Capital allocation plans discussed in general terms; no specific buyback, dividend, or capex amounts provided
  • Management highlights regulatory, market, supply chain, labor, and technology risks affecting future operations and growth

AI summary of the DVA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Nine-month revenue $10.548B, up 5.2% YoY from $10.023B
  • U.S. dialysis revenue $9.004B, up 3.3% YoY, strongest segment
  • Operating income $1.560B, up 5.2% YoY from $1.483B, operating margin figures not provided
  • Operating cash flow $1.330B vs $1.346B YoY, share repurchases $870M for 5.837M shares
  • Headwinds: commercial mix pressure, rising labor and supply costs, policy uncertainty, China impairment charges of $62M

Risk Factors

  • No material changes to risk factors disclosed in the 2025 10-K
  • Carried-forward risk: forward-looking statements in quarterly Management’s Discussion and Analysis
  • Carried-forward risk: risks detailed in the 2025 10-K remain applicable

AI summary of the DVA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $3.578B, operating income $499M, adjusted EPS $3.82, with adjusted operating margin 15.7%
  • Adjusted 2026 operating-income guidance raised to $2.175B-$2.250B from prior low of $2.150B

Item 2.02: Results of Operations and Financial Condition

  • DaVita announced financial results for the quarter ended September 30, 2026
  • Full revenue, earnings and operating details are in Exhibit 99.1, the attached earnings release
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $3.554B and operating income $579M, with operating margin expanding to 16.3% from 14.1% in Q1
  • Diluted EPS $4.02 versus $2.87 in Q1, supported by net income attributable to DaVita Inc. of $265M

Item 2.02: Results of Operations and Financial Condition

  • DaVita announced financial results for the quarter ended June 30, 2026
  • Detailed operating metrics and financial figures are in Exhibit 99.1, the accompanying earnings release
Filed Jun 8, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 disclosure is incomplete, providing no amount, terms, interest rate, maturity, or borrowing purpose
  • Investors should review the filing’s exhibits for the underlying financial obligation details

Item 1.01: Entry into a Material Definitive Agreement

  • $500M incremental borrowing under senior secured Tranche B-2 term facility maturing May 2031
  • Interest: Term SOFR plus 175 basis points or Base Rate plus 75 basis points

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 59,865,902 shares represented, approximately 91% of outstanding shares, indicating strong shareholder participation
  • All nine director nominees elected for terms expiring at the 2027 annual meeting

AI summaries of DVA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DVA

Don't miss the next DVA filing

  • Alerts as it files. A push when DVA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DVA, by share count.
  • Ask anything. An AI agent that reads every DVA filing and answers with sources.

DVA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schoppert Wendy LeeANov 15, 2026-
Moore Gregory J.ANov 15, 2026-
Schechter Adam HANov 15, 2026-
DESOER BARBARA JANov 15, 2026-
Arway Pamela MANov 15, 2026-
Hollar Jason M.ANov 15, 2026-
BERRY CHRISTOPHER MICHAELFNov 15, 2026$174.56
Rodriguez JavierFNov 15, 2026$174.56

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$12.8B$13.6B
Operating Income-$2.1B$2.0B
Net Income$691.5M$936.3M$746.8M
Op. Margin-16.3%15.0%
Net Margin-7.3%5.5%
Balance Sheet
Total Assets$16.9B$17.3B$17.5B
Equity-$121.1M-$651.1M
ROE-773.1%-114.7%
Per Share
EPS$7.42$10.73$9.84
Cash Flow
Operating CF-$2.0B$1.9B
CapEx$568.0M$555.4M$575.9M

Source: XBRL data in DaVita (DVA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DVA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DVA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$7.82B
Q2 202637$9.85B
Q1 202636$7.11B
Q4 202534$5.55B
Q3 202533$6.65B
Q2 202532$7.50B
Q1 202530$7.60B
Q4 202428$7.33B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 266 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DVA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
8-KOct 29, 2026Analysis-
4Oct 29, 2026--
10-QOct 29, 2026Analysis
4Sep 24, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 4, 2026--
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-

Related Health Care companies

All Health Care →

DVA SEC filings: frequently asked questions

Are DVA insiders buying or selling?

In the last 90 days, DaVita (DVA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $69.0 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold DVA stock?

As of September 30, 2026, the largest DaVita (DVA) holders among the 13F filers tracked by SignalX were Berkshire Hathaway Inc ($5.0 billion), BlackRock ($478.2 million), Vanguard Capital Management LLC ($395.2 million), Morgan Stanley ($287.2 million), Vanguard Portfolio Management LLC ($275.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DVA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), DaVita (DVA) reported revenue of $13.6 billion (up 6.5% from FY2024) and net income of $746.8 million. Diluted EPS was $9.84. The figures come from the XBRL data in the 10-K.

What are the main risks in DVA's latest 10-K?

In the 10-K filed February 11, 2026, DaVita (DVA) flagged: Legal risk: accrual for potential third-party judgment costs of $25 million for unspecified legal matters. Macroeconomic exposure: $10.16 billion long-term debt principal maturity with $5.29 billion due after 2030. (AI summary of the Risk Factors section.)

What did DVA report in its latest 8-K?

DaVita (DVA) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $3.578B, operating income $499M, adjusted EPS $3.82, with adjusted operating margin 15.7%.

What are the latest DVA SEC filings?

DaVita (DVA) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.

What is DVA's SEC CIK number?

DaVita (DVA)'s SEC Central Index Key (CIK) is 927066. EDGAR lists every DVA filing under that number.

Ask anything about DVA

The research agent reads DVA's filings, financials, insider trades and 13F holders, then answers with sources.